Mood and Anxiety Symptoms in Persons Taking Prescription Opioids: A Systematic Review with Meta-Analyses of Longitudinal Studies.

"the review was conducted as part of a registered protocol (prospero ascension crd42019128510; see supplementary data s1) following the preferred reporting items for systematic reviews and meta-analyses (prisma) guidelines (see supplementary data s2).; we searched for (opioids search terms) and ((depression search terms) or (bipolar search terms) or (anxiety search terms) or (post-traumatic stress disorder [ptsd] search terms)) using a title or abstract search and database-specific searchers (pubmed: medical subject heading [mesh] terms embase: emtree terms; psycinfo index terms; see supplementary data s3).; then abstracts and full texts were screened against the inclusion criteria (see figure 1 for screening flow; see supplementary data s4 for inclusion and exclusion criteria).; risks of biases were assessed with the newcastle ottawa quality assessment scale for cohort studies (see supplementary data s6 ).; of these 8053 titles/abstracts were excluded (see figure 1 ) in line with our inclusion and exclusion criteria (see supplementary data s4) potential studies identified from the supplementary search had already been identified from the database search.; the included studies were of high quality (average score = 81%; see supplementary data s7).; at a minimum all studies adjusted for key potential confounding variables (e g age sex the severity of injury in patient studies) with half also adjusting for other substance use and other mental health comorbidities (see supplementary data s7).; a summary of unadjusted and adjusted estimates of mental health effects after opioid use and opioid use disorder are presented in table 2 (data available in supplementary data s4).; data available in supplementary data s4.; data available in supplementary data s4.; these were approximately symmetrical and the tests for funnel plot asymmetry were not statistically significant ( supplementary data s4)."

" : Conflicts of interest: In the past three years, LD has received funding from Indivior and Seqirus for studies of new opioid medications in Australia. These funders had no involvement in decision to conduct this study, in its design, data analysis or any other aspect of this study. The other authors declare no conflicts of interest.: Study registration: PROSPERO ascension number CRD42019128510."

"We acknowledge the assistance of Miranda Newell, specialist librarian from The University of Queensland, for her assistance with the database search. NCYSUR and NDARC are supported by funding from the Australian Government provided under the Commonwealth Drug and Alcohol Program grant. JL and TM acknowledge funding support from The University of Queensland. JL, SC-F, and LD are supported by National Health and Medical Research (NHMRC). SC-F is supported by a Scientia PhD Scholarship from UNSW. The funders had no role in study design, data collection and analysis, decision to publish, decision on where to publish, or preparation of the manuscript.  : Conflicts of interest: In the past three years, LD has received funding from Indivior and Seqirus for studies of new opioid medications in Australia. These funders had no involvement in decision to conduct this study, in its design, data analysis or any other aspect of this study. The other authors declare no conflicts of interest.: Study registration: PROSPERO ascension number CRD42019128510."

"The review was conducted as part of a registered protocol (PROSPERO ascension CRD42019128510; see S1) following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines (see S2). Articles in any language were eligible for inclusion.  : Conflicts of interest: In the past three years, LD has received funding from Indivior and Seqirus for studies of new opioid medications in Australia. These funders had no involvement in decision to conduct this study, in its design, data analysis or any other aspect of this study. The other authors declare no conflicts of interest.: Study registration: PROSPERO ascension number CRD42019128510."